Filing Details

Accession Number:
0000950170-24-016710
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-16 21:42:07
Reporting Period:
2024-02-14
Accepted Time:
2024-02-16 21:42:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643734 D. Eric Shaff C/O Seres Therapeutics, Inc.
101 Cambridge Park Drive
Cambridge MA 02140
Ceo And President No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-02-15 31,250 $0.00 146,870 No 4 M Direct
Common Stock Disposition 2024-02-16 11,549 $1.08 135,321 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-02-14 637,500 $0.00 637,500 $1.10
Common Stock Stock Option (Right to Buy) Acquisiton 2024-02-14 822,580 $0.00 822,580 $1.10
Common Stock Restricted Stock Units Acquisiton 2024-02-14 106,250 $0.00 106,250 $0.00
Common Stock Restricted Stock Units Disposition 2024-02-15 31,250 $0.00 31,250 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
637,500 2034-02-13 No 4 A Direct
822,580 2034-02-13 No 4 A Direct
106,250 No 4 A Direct
93,750 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  3. The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.1101, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
  5. The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
  6. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  7. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.